HomeFocusInterviewsFrom research partnerships to development decisions: Abu Dhabi's translational opportunity

From research partnerships to development decisions: Abu Dhabi’s translational opportunity

David-Adler
Professor David Adler, Chief Scientific & Medical Officer of the PATHORA Institute of Pathology & Tissue Medicine

In this follow-up interview, Professor David Adler, Chief Scientific & Medical Officer of the PATHORA Institute of Pathology & Tissue Medicine, discusses how early pharmaceutical-development input could help researchers assess the therapeutic potential of their discoveries. Drawing on more than 15 years in oncology research and development, including a decade in senior leadership at Bayer, he considers practical approaches for Abu Dhabi, the distinction between genomic information and therapeutic evidence, and ways to assess translational progress. The discussion follows his recent Middle East Health article, From discovery to medicine, Abu Dhabi’s advantage could be timing.

Q1. Middle East Health: In your recent article, you argued that Abu Dhabi’s advantage in developing its life-sciences ecosystem could be one of timing. What does this mean in practice, and why can the timing of pharmaceutical-development input be so important?

Professor David Adler: It means introducing development questions while researchers can still change their experimental plans. In early discovery, the emphasis is often on demonstrating that a biological mechanism contributes to disease. Drug development requires a further judgement about whether that mechanism can be altered by a treatment at a tolerable exposure in patients who can be identified.

For example, genetically disabling a cancer-related protein may slow tumour growth in a laboratory model. However, this does not necessarily mean that targeting the same protein with a drug will benefit patients. A development specialist might ask whether the protein can be targeted pharmacologically, whether an effective treatment could be achieved without unacceptable toxicity, and whether the findings are relevant to human tumours.

Those questions may redirect the next experiment towards human-sample validation or pharmacological testing. If raised only when licensing or investment is being considered, important assumptions may already be embedded in years of work. The point is not to impose clinical-development requirements on fundamental science, but to offer appropriate expertise when a plausible therapeutic application begins to emerge.

Q2. Middle East Health: Abu Dhabi has invested significantly in research institutions, healthcare infrastructure, genomics, and international partnerships. How can it ensure that these investments translate into meaningful support for individual research programmes seeking to develop new medicines?

Professor David Adler: The critical distinction is between connecting institutions and helping individual research teams make better decisions. Abu Dhabi’s HELM cluster and the agreements announced with MIT and Sanford Burnham Prebys provide important foundations. The practical question is whether a researcher can obtain advice on a specific development problem without first forming a company or preparing a commercial proposal.

One approach would be to offer voluntary, project-level consultations involving relevant expertise in areas such as translational pharmacology, clinical oncology and biomarker development for a proposed cancer target. The investigators would bring a defined hypothesis and the uncertainty they are struggling to resolve.

The useful output would not simply be a general endorsement, but rather a focused scientific assessment identifying what evidence is missing, which experiments could discriminate between alternative explanations, and what results would justify continuing, changing direction or stopping a programme. Existing universities and research partnerships could organise this support; however, its value would depend on ensuring that the advice reaches the researchers designing the experiments and helps inform their scientific decisions, rather than becoming another administrative review.

Q3. Middle East Health: You are currently developing an initiative in Israel to bring pharmaceutical-industry expertise into academic research at an earlier stage. What are the main components of this initiative, and how could a similar model be implemented in Abu Dhabi?

Professor David Adler: The initiative I conceived and am developing with the Hebrew University of Jerusalem and Ben-Gurion University of the Negev has three complementary elements.

First, I have developed a practical course on pharmaceutical research and development, with commitments from senior pharmaceutical and biotechnology executives to contribute and initial sessions planned for early 2027. The emphasis is on the scientific and strategic decisions involved in progressing from discovery through preclinical research and early clinical development, not simply on describing the stages of drug development.

Second, the initiative aims to create direct opportunities for academic investigators to engage with experienced industry scientists. Third, I have proposed a Pharma-Academic Strategic Task Force to examine selected discoveries, clarify the principal development uncertainties and explore relevant connections.

These elements are at different stages of preparation; their effectiveness has not yet been demonstrated. Abu Dhabi could adapt the functions rather than copy the structure, drawing on existing academic and international partnerships. The essential requirement is sustained access to experienced judgement while research programmes are still scientifically flexible.

Q4. Middle East Health: Not every scientific discovery has the potential to become a medicine. How could researchers identify which discoveries would benefit most from early involvement of pharmaceutical-development specialists?

Professor David Adler: I would begin with three questions. Is there credible evidence linking the mechanism to human disease? Is there a plausible way to intervene therapeutically? And is there a specific uncertainty that a feasible experiment could resolve? A drug candidate does not need to exist at this stage.

For instance, a pathway may be associated with aggressive tumour behaviour, but association alone does not establish that inhibiting it will help patients. A specialist might recommend testing whether the tumour remains dependent on that pathway, assessing whether its inhibition could interfere with essential functions in healthy tissues, or investigating whether a suitable therapeutic approach is feasible.

The purpose is not to rank discoveries by commercial appeal or apply a premature development checklist, but rather to identify the evidence most likely to inform the next decision. In some cases, this may indicate that further fundamental research is needed, while in others, it may suggest that a therapeutic hypothesis is unlikely to be viable. However, such conclusions do not diminish the value of the underlying research; instead, they help clarify whether further efforts towards developing a medicine are scientifically justified.

Q5. Middle East Health: Abu Dhabi is developing substantial capabilities in genomics, clinical data, biobanking, and clinical research. How could these resources help researchers establish whether promising laboratory discoveries are relevant to human disease and potential treatments?

Professor David Adler: These resources are useful when they are linked to a particular therapeutic question. A target that appears important in a cell line may be expressed differently across patients, tumour types or stages of treatment. Well-characterised tumour samples, linked where appropriate to clinical information, can help test whether the proposed mechanism is relevant in the population a future medicine would be intended to treat.

Different datasets answer different questions, as population genomics can reveal inherited variation and susceptibility to disease, while tumour sequencing can identify acquired molecular changes. However, neither approach, on its own, demonstrates that interfering with a particular target will produce clinical benefit, which ultimately requires supporting functional, pharmacological and clinical evidence.

Researchers also need to consider sample quality, treatment history, tumour heterogeneity and whether observations can be reproduced in independent samples. Abu Dhabi’s biobanking and health-data infrastructure could help address these challenges by providing access to well-characterised human samples and associated clinical information, while ensuring appropriate patient consent, privacy safeguards and data governance. The real advantage, therefore, lies not simply in having more data, but in generating the human evidence needed to challenge or strengthen a therapeutic hypothesis.

Q6. Middle East Health: Looking five to ten years ahead, what would meaningful success look like for Abu Dhabi in translating scientific research into new medicines, beyond establishing institutions and international partnerships?

Professor David Adler: Meaningful success would include the emergence of innovative biotechnology companies, valuable intellectual property and substantive development partnerships, particularly where these attract investment and support the advancement of promising therapeutic programmes. However, over a five-to-ten-year period, I would also hope to see therapeutic candidates originating from Abu Dhabi’s research institutions progressing into clinical development, with some generating meaningful evidence of clinical activity in Phase II trials and potentially advancing into late-stage development.

Such progress would demonstrate that Abu Dhabi’s research ecosystem is capable not only of generating scientific discoveries, but also of translating them into therapeutic candidates that can be evaluated in patients. Equally important would be the establishment of sustained partnerships with pharmaceutical and biotechnology companies that bring the expertise, resources and development capabilities needed to advance these programmes.

At the same time, success should not be measured solely by how many programmes advance, since well-supported decisions to redirect or discontinue less promising projects are also important for concentrating resources on opportunities with greater therapeutic potential.

Ultimately, the strongest evidence of success would be medicines originating from research in Abu Dhabi that demonstrate meaningful clinical benefits for patients. Although achieving this goal may extend beyond ten years, establishing a credible pipeline of innovative therapies progressing through clinical development would represent tangible evidence of a successful translational research ecosystem.

- Advertisment -

Most Popular